[Skip to Navigation]
Editor's Note
March 3, 2021

Reconsidering the Ross Procedure

Author Affiliations
  • 1Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • 2Editor, JAMA Cardiology
  • 3Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
  • 4Deputy Editor, JAMA Cardiology
JAMA Cardiol. 2021;6(5):548. doi:10.1001/jamacardio.2021.0087

There is no perfect prosthetic valve substitute for young and middle-aged patients requiring aortic valve replacement (AVR). The long-term risks of anticoagulation with a mechanical prosthesis must be weighed against the risks of structural valve deterioration of a bioprosthetic valve. In patients aged 20 to 40 years, the decision almost always leads to the selection of a mechanical valve and lifelong anticoagulation. Unfortunately, aortic valve repair is an option for only a small number of patients who are highly selected.

Add or change institution